

Cell Therapy

Part I: Technologies, Ethics & Regulations

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech.

Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. He has also written a textbook of gene therapy which is the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons and the 2017 version is included in a special report on gene therapy published by Jain PharmaBiotech. Other reports written by Prof. Jain have been published by PJB Publications, D & MD, Reuter's Business Insight, and Decision Resources Inc. Cell Therapy is one of the several in-house publications of Jain PharmaBiotech.

Prof. Jain's recent books include "Handbook of Nanomedicine" (1st ed by Springer 2008, Chinese ed by Peking University Press 2011, 2nd edition 2012, 3rd ed 2017 by Springer), "Textbook of Personalized Medicine" (1st ed by Springer 2009; Japanese edition 2012; 2nd ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016; 2nd edn Springer 2017), Handbook of Neuroprotection (Springer 2011), Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011), Applications of Biotechnology in Neurology (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Applied Neurogenomics" (Springer 2015).

**November 2017 (first edition published July 2001)
Copyright © 2017 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	27
1. Introduction to Cell Therapy	31
Introduction.....	31
Historical landmarks of cell therapy.....	31
Interrelationship of cell therapy technologies	33
Cells and organ transplantation	34
Cells and protein/gene therapy	34
Cell therapy and regenerative medicine	35
Cell therapy and tissue engineering	36
Therapy based on cells involved in disease	36
Advantages of therapeutic use of cells.....	37
Synthetic cell therapy	37
Cell-based drug delivery	38
<i>Cells as vehicles for gene delivery</i>	<i>38</i>
<i>Red blood cells as vehicles for drug delivery</i>	<i>38</i>
<i>Advantages of cell-based drug delivery.....</i>	<i>40</i>
<i>Limitations of cell-based drug delivery.....</i>	<i>40</i>
2. Cell Therapy Technologies	41
Introduction.....	41
Cell types used for therapy	41
Sources of cells.....	41
Bone marrow.....	42
Blood component therapy	42
<i>Therapeutic apheresis.....</i>	<i>42</i>
<i>Leukoreduction</i>	<i>43</i>
<i>Platelet therapy</i>	<i>43</i>
<i>Red blood cell transfusion</i>	<i>43</i>
Cell lines.....	44
<i>Immortalized cells.....</i>	<i>44</i>
Xenografts	45
Basic technologies for cell therapy	45
Cell culture.....	45
<i>Automated cell culture devices.....</i>	<i>45</i>
<i>Cell culture for adoptive cell therapy.....</i>	<i>46</i>
<i>Observation of stem cell growth and viability</i>	<i>46</i>
<i>OpTmizer™ CTS™ T cell expansion tissue culture medium.....</i>	<i>46</i>
<i>Companies involved in cell culture.....</i>	<i>46</i>
Cell sorting.....	48
<i>Flow cytometry</i>	<i>48</i>
<i>Applications of flow cytometry</i>	<i>49</i>
<i>A dielectrophoretic system for cell separation</i>	<i>49</i>
<i>Adult stem cell sorting by identification of surface markers.....</i>	<i>50</i>
<i>ALDESORTER system for isolation of stem cells.....</i>	<i>50</i>
<i>Dynabead technology for cell sorting</i>	<i>50</i>
<i>Elutra® Cell Separation System.....</i>	<i>51</i>
<i>Magnetophoretic array-based cell sorting for further studies.....</i>	<i>51</i>
<i>Molecular beacons for specific detection and isolation of stem cells.....</i>	<i>51</i>
<i>Multitarget magnetic activated cell sorter.....</i>	<i>51</i>
<i>Nanocytometry</i>	<i>52</i>
<i>Scepter™ cytometer.....</i>	<i>52</i>
<i>Companies supplying cell sorters</i>	<i>52</i>
Cell analysis	53
<i>Cell analyzers</i>	<i>54</i>
<i>In vivo cell imaging</i>	<i>54</i>
<i>Measuring cell density</i>	<i>55</i>
Single-cell gene expression analysis	55
<i>Fluorescent in situ RNA sequencing</i>	<i>56</i>
<i>Single-cell RNA sequencing of stem cells.....</i>	<i>56</i>
Preservation of cells	57
<i>Innovations in cryopreservation</i>	<i>57</i>
Packaging of cells.....	58
Selective expansion of T cells for immunotherapy	59
Cloning and cell therapy	59
Techniques for cell manipulation	60
Altering function of adult human cells	60

Cell-based drug discovery	60
Advantages and limitations of cell-based assays for drug discovery	61
<i>Advantages and limitations of cell-based toxicity screening</i>	61
<i>Quality control of cells for drug discovery</i>	61
Companies involved in cell-based drug discovery	62
Introduction of foreign materials into cells to develop therapeutics	63
Use of cell-penetrating peptides for intracellular transduction	64
Drug delivery systems for cell therapy	64
Intravenous delivery of stem cells.....	64
Intraarterial delivery of stem cells.....	65
Pharmacologically active microcarriers.....	65
Targeted delivery of engineered cells to specific tissues via circulation	66
Devices for delivery of cell therapy.....	66
Artificial cells	67
Applications of artificial cells.....	67
Cell encapsulation	67
Cell-in-a-Box®	68
Diffusion capsule for cells.....	68
Encapsulated cell biodelivery	68
Therapeutic applications of encapsulated cells	69
Nitric oxide delivery by encapsulated cells.....	70
Implantation of microencapsulated genetically modified cells	71
Ferrofluid microcapsules for tracking with MRI	71
Companies involved in encapsulated cell technology.....	71
Electroporation	72
Gene therapy	72
Cell-mediated gene therapy	73
<i>Fibroblasts</i>	73
<i>Chondrocyte</i>	74
<i>Skeletal muscle cells</i>	74
<i>Vascular smooth muscle cells</i>	75
<i>Keratinocytes</i>	75
<i>Hepatocytes</i>	75
<i>Lymphocytes</i>	76
Cell-based CRISPR delivery	76
In vivo tracking of cells	76
Molecular imaging for tracking cells.....	77
<i>MRI technologies for tracking cells</i>	77
<i>Superparamagnetic iron oxide nanoparticles as MRI contrast agents</i>	78
<i>Survival of labeled hMSCs in regenerative therapy grafts</i>	79
<i>Visualization of gene expression in vivo by MRI</i>	79
Optogenetic monitoring of cell therapies	79
Role of nanobiotechnology in development of cell therapy	80
Nano-biocomposites containing living cells	80
Cell transplantation for development of organs	81
Cells transplantation and tolerance	81
Strategies to improve tolerance of transplanted cells.....	81
<i>Encapsulation to prevent immune rejection</i>	81
<i>Expansion of allospecific regulatory T cells</i>	82
<i>Prevention of rejection of xenotransplants</i>	82
Removal and replacement of pathogenic cells of the body	83
Therapeutic leukocytapheresis.....	83
3. Stem Cells	85
Introduction	85
Biology of stem cells	85
Embryonic stem cells.....	86
Growth and differentiation of ESCs.....	86
Mechanisms of differentiation of ESCs.....	87
<i>Chemical regulation of stem cell differentiation</i>	87
<i>In vitro differentiation of hESCs</i>	87
<i>SIRT1 regulation during stem cell differentiation</i>	88
Regulation of stem cell self-renewal and differentiation.....	88
<i>hESCs for reprogramming human somatic nuclei</i>	88
<i>Stem cells differentiation in the pituitary gland</i>	89
Influence of microenvironment on ESCs.....	89
Role of genes in differentiation of ESCs.....	89
<i>Global transcription in pluripotent ESCs</i>	89
<i>Role of p53 tumor suppressor gene in stem cell differentiation</i>	90
<i>Role of Pax3 gene in stem cell differentiation</i>	90
<i>Signaling pathways and ESC genes</i>	90

Epigenetics of hESCs	91
<i>Chromatin as gene regulator for ESC development</i>	92
Mechanism of regulation of stem cells for regeneration of body tissues	92
<i>Role of microenvironments in the regulation of stem cells</i>	92
<i>Regulation and regeneration of intestinal stem cells</i>	93
Parthenogenesis and human stem cells	93
<i>Uniparental ESCs</i>	94
<i>Haploid ESCs</i>	94
Bone marrow stem cells	95
Hematopoietic stem cells	95
<i>Clonal events that regulate HSC development</i>	97
<i>Derivation of HSCs from ESCs</i>	97
<i>Role of HSCs in the immune system</i>	97
Mesenchymal stem cells	98
<i>Cryopreservation of MSCs</i>	99
Multipotent adult progenitor cells	100
Side population stem cells	100
Differentiation of adult stem cells	101
Growth and differentiation of HSCs	102
<i>HSCs and aging</i>	102
<i>Mathematical modeling of differentiation of HSCs</i>	102
<i>Role of prions in self renewal of HSCs</i>	103
<i>Signaling pathways in the growth and differentiation of HSCs</i>	103
Sources of stem cells	103
Sources of human embryonic stem cells	103
Nuclear transfer to obtain hESCs	104
Direct derivation of hESCs from embryos without nuclear transfer	105
Alternative methods of obtaining hESCs	105
<i>Establishing hESC lines without destruction of embryo</i>	105
<i>Altered nuclear transfer</i>	106
Advantages and disadvantages of ESCs for transplantation	107
Use of ESC cultures as an alternative source of tissue for transplantation	107
Spermatogonial stem cells	108
Very small embryonic-like stem cells	109
Amniotic fluid as a source of stem cells	109
<i>Amniotic fluid stem cells for tissue repair and regeneration</i>	109
<i>Generation of iPS cells from AF cells</i>	110
Placenta as source of stem cells	110
<i>Amnion-derived multipotent progenitor cells</i>	110
<i>Placenta as a source of HSCs</i>	111
<i>Umbilical cord as a source of MSCs</i>	111
Umbilical cord blood as source of neonatal stem cells	112
<i>Cryopreservation of UCB stem cells</i>	113
<i>Epigenetic programming for expansion of UCB cells</i>	113
<i>UCB as source of MSCs</i>	113
<i>Applications of UCB</i>	114
<i>Advantages of UCB</i>	114
<i>Limitations of the use of UCB and measures to address them</i>	115
<i>Licensing and patent disputes involving UCB</i>	116
<i>Infections following UCB transplants</i>	116
<i>Unanswered questions about UCB transplantation</i>	117
<i>Companies involved in UCB banking</i>	117
<i>UCB banking in the UK</i>	119
<i>US national UCB banking system</i>	119
<i>Future prospects of UCB</i>	120
Techniques of nuclear reprogramming for stem cells	121
Induced pluripotent stem cells derived from human somatic cells	121
Characteristics of iPSCs	121
DNA methylation patterns of iPSCs	122
Techniques for obtaining iPSCs	122
iPSCs derived from skin	122
iPSCs derived through somatic cell nuclear transfer (SCNT)	123
<i>iPSCs derived from oocytes</i>	123
<i>iPSCs derived from adult stem cells using SCNT</i>	123
iPSCs derived from blood	123
Use of retroviral vectors for generation of iPSCs	124
Use of non-integrating viral vectors for generation of iPSCs	124
Generation of other cells from iPSCs	125
<i>Generation of HSCs from iPSCs</i>	125
<i>Generation of MSCs from iPSCs</i>	125
<i>Generation of RBCs from iPSCs</i>	126

Banks providing patient-specific iPSC lines	126
Center for iPSC Cell Research Application	126
Companies providing iPSCs	127
Generation of clinically relevant iPSCs	127
<i>Equivalence of human iPSCs and ESCs</i>	128
<i>Genome editing and iPSCs</i>	128
<i>iPSCs and disease modeling</i>	129
<i>iPSCs for patient-specific regenerative medicine</i>	129
<i>Concluding remarks about clinical potential of iPSCs</i>	130
Induced conditional self-renewing progenitor cells	131
iXEN cells	131
Epiblast stem cells	131
Comparison of development of human and mouse ESCs	131
Conversion of hESCs to mouse ESC-like naïve states	132
Sources of adult human stem cells	132
Adipose tissue as a source of stem cells	133
<i>Encapsulation and hypothermic storage of adipose-derived stem cells</i>	133
<i>Intravenous infusion of adipose tissue derived MSCs</i>	134
<i>iPSCs derived from adult human adipose stem cells</i>	134
<i>Regulation of adipose stem cells differentiation</i>	134
<i>Transforming adult adipose stem cells into other cells</i>	134
Endometrium as a source of adult stem cells	135
Multipotent stem-like cells derived from vascular endothelial cells	135
Skin as a source of stem cells	135
<i>Controlling the maturation of embryonic skin stem cells</i>	135
<i>Epidermal neural crest stem cells</i>	136
<i>Follicle stem cells</i>	136
<i>Mesenchymal stem cells in skin</i>	137
<i>Regulation of stem cells in hair follicles</i>	137
<i>Skin-derived precursor cells</i>	137
Regulation of epidermal stem cells by circadian rhythms	138
Stem cells in teeth	138
Peripheral blood stem cells	139
Spleen as a source of adult stem cells	139
Search for master stem cells	139
Vascular cell platform to self-renew adult HSC	140
Adult stem cells vs embryonic stem cells	140
Biological differences between adult and embryonic stem cells	140
Neural crest stem cells from adult hair follicles	141
Transdifferentiation potential of adult stem cells	141
Attempts at stimulus-triggered acquisition of pluripotency	142
Limitations of adult stem cells	143
Pitfalls of pluripotency	143
Comparison of human stem cells according to derivation	144
VENT cells	144
ESC banking	144
Stem cell technologies	145
Analysis of stem cell growth and differentiation	145
Activation of bone marrow stem cells into therapeutic cells	145
Role of nitric oxide in stem cell mobilization and differentiation	145
Role of natriuretic peptide receptor-C in self-renewal of murine ESCs	146
Stem cell biomarkers	146
<i>Endoglin as a functional biomarker of HSCs</i>	146
<i>STEMPRO® EZChek™ for analysis of biomarkers of hESCs</i>	147
<i>SSEA-4 as biomarker of MSCs</i>	147
<i>p75NTR as a biomarker to isolate adipose tissue-derived stem cells</i>	147
<i>Neural stem cell biomarker</i>	147
<i>Protein expression profile as biomarker of stem cells</i>	148
<i>Real-time PCR for quantification of protein biomarkers</i>	148
Study of stem cell pathways	148
Stem cell genomics	149
<i>Gene expression in hESCs</i>	149
<i>Genomic alterations in cultured hESCs</i>	149
<i>Study of transcriptional regulation of stem cell genes</i>	150
<i>Casanova gene in zebrafish</i>	150
<i>Nanog gene</i>	150
Gene inactivation to study hESCs	151
<i>RNAi to study gene inactivation in hESCs</i>	152
<i>Study of ESC development by inducible RNAi</i>	152
<i>Targeting Induced Local Lesions in Genomes</i>	153
<i>Homologous recombination of ESCs</i>	153

Gene modification in genomes of hESCs and hiPSCs using zinc-finger nuclease.....	153
miRNA and stem cells	154
<i>Role of miRNAs in gene regulation during stem cell differentiation</i>	154
<i>Influence of miRNA on stem cell formation and maintenance</i>	154
<i>Transcriptional regulators of ESCs control miRNA gene expression</i>	155
Stem cells and cloning	155
<i>Cell nuclear replacement and cloning</i>	155
<i>Nuclear transfer and ESCs</i>	156
<i>Cloning from differentiated cells</i>	157
<i>Cloning mice from adult stem cells</i>	157
<i>Creating interspecies stem cells</i>	158
<i>Cloned cells for transplantation medicine</i>	158
<i>Claims of cloning of hESCs</i>	159
<i>hESCs derived by SCNT</i>	160
Cytogenetics of embryonic stem cells	161
Stem cell proteomics	161
<i>Comparative proteomic analysis of somatic cells, iPSCs and ESCs</i>	162
<i>hESC phosphoproteome</i>	162
<i>Proteomic studies of mesenchymal stem cells</i>	163
<i>Proteomic profiling of neural stem cells</i>	163
<i>Proteome Biology of Stem Cells Initiative</i>	163
Technologies for mobilization, expansion, and engraftment of stem cells.....	164
<i>Chemoattraction of neuronal stem cells through GABA receptor</i>	164
<i>Enhancement of HSC engraftment by calcium-sensing receptor</i>	165
<i>Ex vivo expansion of human HSCs in culture</i>	165
<i>Ex vivo expansion of MSCs</i>	166
<i>Ex vivo expansion of UCB cells for transplantation</i>	166
<i>Expansion of adult stem cells by activation of Oct4</i>	166
<i>Expansion of transduced HSCs in vivo</i>	166
<i>Expansion of stem cells in vivo by Notch receptor ligands</i>	167
<i>In vivo adipogenesis induced by adipose tissue-derived stem cells</i>	167
<i>Selective mobilization of progenitor cells from bone marrow</i>	167
<i>Selective Amplification</i>	168
<i>Synthetic substrates for ESC growth and expansion</i>	168
Technologies for inducing differentiation of stem cells.....	168
<i>Enhancement of stem cell differentiation by Homspera</i>	168
<i>Generation of RBCs from HSCs</i>	169
<i>Generation of multiple types of WBCs from hESCs and iPSCs</i>	169
<i>Growth factor-induced differentiation of MAPCs</i>	169
<i>Lineage selection to induce differentiation of hESCs</i>	170
<i>Mechanical strain to induce MSC differentiation</i>	170
<i>Neurotrophin-mediated survival and differentiation of hESCs</i>	170
<i>Synthetic biology and stem cells</i>	171
<i>Use of RNAi to expand the plasticity of autologous adult stem cells</i>	171
<i>Use of various molecules to induce differentiation of stem cells</i>	172
Limitations of the currently available stem cell lines in the US	172
Stem cell separation	172
Stem cell culture.....	173
<i>Culture of hMSCs</i>	174
<i>Elimination of contaminating material in stem cell culture</i>	174
<i>Long-term maintenance of MSC multipotency in culture</i>	175
<i>Nanofiber scaffolds for stem cell culture</i>	176
Conversion of stem cells to functioning adipocytes	176
Mass production of ESCs	176
Promoting survival of dissociated hESCs	177
Analysis and characterization of stem cells	177
Harvesting and identification of EPCs	178
Labeling of stem cells	178
Labeling, imaging and tracking of stem cells in vivo	179
<i>Perfluorocarbon nanoparticles to track therapeutic cells in vivo</i>	179
<i>PET imaging for tracking of stem cells</i>	179
<i>Project for imaging in stem cell therapy research</i>	179
<i>Quantum dots for labeling and imaging of stem cells</i>	180
<i>Radiolabeling of MSCs for in vivo tracking</i>	180
<i>Superparamagnetic iron oxide nanoparticles for tracking MSCs</i>	180
<i>Tracking of transplanted muscle stem cells</i>	181
Applications of stem cells	181
Commercial development and applications of adult stem cells.....	182
<i>Preparation of cells for therapeutic administration to patients</i>	182
<i>Retrodifferentiation of stem cells</i>	182
<i>MultiStem</i>	182

Controlling the maintenance process of hematopoietic stem cells	183
<i>Self renewal and proliferation of HSCs</i>	183
<i>Aging and rejuvenation of HSCs</i>	183
<i>Aging and MSCs</i>	184
iPSC-based modeling of late-onset age-related diseases	184
Peripheral blood stem cell transplantation	184
Role of stem cells in regeneration	185
<i>Pluripotent stem-cell-derived gastric organoids</i>	185
<i>Promotion of regeneration by Wnt/beta-catenin signaling</i>	185
<i>Stem cell activation for regeneration by using glucocorticoids</i>	186
Stem cells and human reproduction	186
<i>Expansion of spermatogonial stem cells</i>	186
<i>Conversion of ESCs into spermatogonial stem cells</i>	186
<i>Conversion of stem cells to oocytes</i>	187
<i>ESCs for treatment of infertility in women</i>	187
<i>Cloning human embryos from oocytes matured in the laboratory</i>	188
<i>In utero stem cell transplantation</i>	188
Innovations in delivery of stem cells.....	189
<i>Polymeric capsules for stem cell delivery</i>	190
Immunological aspects of hESC transplantation	190
<i>Immunosuppression to prevent rejection of hESC transplants</i>	190
<i>Histocompatibility of hESCs</i>	191
<i>Strategies for promoting immune tolerance of hESCs</i>	191
Stem cells for organ vascularization	192
<i>Activation of EphB4 to enhance angiogenesis by EPCs</i>	192
Advantages and limitations of clinical applications of iPSCs.....	193
Advantages and limitations of clinical applications of MSCs.....	193
Biofusion by genetically engineering stem cells	193
Stem cell gene therapy	194
<i>Combination of gene therapy with nuclear transfer</i>	194
<i>Gene delivery to stem cells by artificial chromosome expression</i>	194
<i>Genetic manipulation of ESCs</i>	195
<i>Genetic engineering of human stem cells for enhancing angiogenesis</i>	195
<i>HSCs for gene therapy</i>	195
<i>iPSCs for targeted gene correction of α1-antitrypsin deficiency</i>	196
<i>Helper-dependent adenoviral vectors for gene transfer in ESCs</i>	196
<i>Lentiviral vectors for in vivo gene transfer to stem cells</i>	197
<i>Linker based sperm-mediated gene transfer technology</i>	197
<i>Mesenchymal stem cells for gene therapy</i>	197
<i>Microporation for transfection of MSCs</i>	198
<i>Regulation of gene expression for SC-based gene therapy</i>	198
<i>Stem cells and in utero gene therapy</i>	198
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i>	199
<i>Targeted genome editing for human repopulating HSCs</i>	199
<i>The future of hematopoietic stem cell gene therapy</i>	199
Stem cell pharmaceuticals	199
Pharmaceutical manipulation of stem cells	200
<i>Expansion of HSCs in culture by inhibiting aldehyde dehydrogenase</i>	200
<i>Expansion of HSCs in vivo by use of prostaglandin E2</i>	201
<i>Manipulation of stem cells with growth factors</i>	201
<i>Mobilization of stem cells by cytokines/chemokines</i>	203
<i>Mobilization of adult human HSCs by use of inhibitors</i>	204
<i>Mobilization of stem cells by HYC750</i>	204
<i>Mobilization of stem cells by hyperbaric oxygen</i>	205
<i>Mobilization by adenoviral vectors expressing angiogenic factors</i>	205
<i>Stem cell mobilization by acetylcholine receptor agonists</i>	205
<i>Use of parathyroid hormone to increase HSC mobilization</i>	206
<i>Use of small molecule compounds for expansion of HSCs</i>	206
<i>Use of a small molecule for targeting systemically infused MSCs</i>	206
Role of stem cells in therapeutic effects of drugs.....	207
Stem cells for drug discovery.....	207
<i>Target identification</i>	207
<i>High-throughput screening</i>	207
<i>ESCs as source of models for drug discovery</i>	208
<i>hESC-derived hepatocytes for drug discovery</i>	208
<i>hESC-derived cardiomyocytes for drug discovery</i>	209
<i>iPSCs for drug discovery</i>	210
<i>Advantages and limitations of use of stem cells for drug discovery</i>	210
Stem cells for drug delivery.....	211
Toxicology and drug safety studies using ESCs versus other cells.....	211
Future challenges for stem cell technologies	214

Generation of patient-specific pluripotent stem cells	214
Hybrid embryos/cybrids for stem cell research	215
In vivo study of human hemopoietic stem cells	215
Inhibition of stem cell-derived teratoma formation by small molecules.....	215
Markers for characterizing hESC lines	216
MBD3-deficient ESC line.....	216
Research into plasticity of stem cells from adults	216
Reversion of human stem cells to ground state pluripotency	217
Stem cell biology and cancer	217
Stem cells and aging	218
Stem cells in space	219
Study of the molecular mechanism of cell differentiation	219
Switch of stem-cell function from activators to repressors	220
Stem cell research at academic centers	220
International Regulome Consortium	221
Companies involved in stem cell technologies	222
Concluding remarks about stem cells.....	227
Challenges and prospects of stem cell research	227

4. Clinical Applications of Cell Therapy **229**

Introduction.....	229
Cell therapy for hematological disorders.....	229
Transplantation of autologous hematopoietic stem cells	229
HSCs derived from pluripotent stem cells	229
Hemophilias	230
<i>Ex vivo cell/gene therapy of hemophilia B</i>	<i>230</i>
<i>Cell/gene therapy of hemophilia A.....</i>	<i>231</i>
Hematopoietic stem cell therapy for thrombocytopenia	231
Stem cell transplant for sickle cell anemia	232
Treatment of chronic acquired anemias.....	232
<i>Implantation of genetically engineered HSCs to deliver rhEpo</i>	<i>233</i>
<i>Drugs acting on stem cells for treatment of anemia</i>	<i>233</i>
Stem cell therapy of hemoglobinopathies	233
<i>iPSC-based therapy for β-thalassemia</i>	<i>234</i>
Stem cells for treatment of immunoglobulin-light chain amyloidosis	234
Future prospects of cell therapy of hematological disorders	234
Cell therapy for immunological disorders	235
Role of dendritic cells in the immune system	235
Modifying immune responses of DCs by vaccination with lipiodol-siRNA mixtures	235
Potential of MSCs as therapy for immune-mediated diseases	236
Stem cell therapy of chronic granulomatous disease.....	236
Stem cell therapy of X-linked severe combined immunodeficiency.....	236
Stem cell therapy of autoimmune disorders	237
<i>Wiskott-Aldrich Syndrome.....</i>	<i>237</i>
<i>Treatment of rheumatoid arthritis with stem cells.....</i>	<i>237</i>
<i>Treatment of Crohn's disease with stem cells.....</i>	<i>238</i>
<i>Stem cell transplants for scleroderma</i>	<i>239</i>
Role of T Cells in immunological disorders	239
<i>Autologous T cells from adult stem cells.....</i>	<i>240</i>
Cell therapy for graft vs host disease.....	240
<i>T cell infusion for suppressing GVHD</i>	<i>241</i>
<i>Genetically modified Tregs expressing CAR for prevention of GVHD</i>	<i>241</i>
<i>MSCs for GVHD.....</i>	<i>242</i>
Cell therapy for viral infections	242
Anti-HIV ribozyme delivered in hematopoietic progenitor cells	242
Dendritic-cell targeted DNA vaccine for HIV	243
Exosomes and viral infections.....	243
Manipulation of T cells for treatment of viral infections.....	243
<i>T cell therapy for CMV</i>	<i>243</i>
<i>T cell therapy for HIV infection.....</i>	<i>244</i>
<i>T cell immunity by Overlapping Peptide-pulsed Autologous Cells</i>	<i>244</i>
Modification of iPSCs with a mutation to confer resistance to HIV	245
Cell therapy of lysosomal storage diseases	245
Niemann-Pick disease	245
Gaucher's disease	246
Fabry's disease	246
Cell therapy for endocrine disorders	247
Hypopituitarism	247
Adrenal insufficiency.....	247
Cell therapy for diabetes mellitus	248
Limitations of current treatment	249

<i>Limitations of insulin therapy for diabetes mellitus</i>	249
<i>Limitations of pancreatic transplantation</i>	249
Islet cell transplantation	249
<i>Autologous pancreatic islet cell transplantation in chronic pancreatitis</i>	250
<i>Clinical trials of pancreatic islet cell transplants for diabetes</i>	250
<i>Drawbacks of islet cell therapy</i>	251
<i>Use of an antioxidant peptide to improve islet cell transplantation</i>	251
<i>Cdk-6 and cyclin D1 enhance human beta cell replication and function</i>	251
<i>Devices for delivery of therapeutic cells in diabetes</i>	252
<i>Monitoring of islet cell transplants with MRI</i>	252
<i>Concluding remarks about allogeneic islet transplantation for diabetes</i>	252
Encapsulation of insulin producing cells.....	253
<i>Encapsulated porcine pancreatic islet cells for pancreas</i>	253
<i>Encapsulated insulinoma cells</i>	254
<i>Magnetocapsule enables imaging/tracking of islet cell transplants</i>	254
Islet precursor cells	254
Dedifferentiation of β cells to promote regeneration	255
Pharmacological approaches for β cell regeneration	255
Xenotransplantation of embryonic pancreatic tissue	256
Non-pancreatic tissues for generation of insulin-producing cells	256
Exploiting maternal microchimerism to treat diabetes in the child	257
Bio-artificial substitutes for pancreas	257
Role of stem cells in the treatment of diabetes	258
<i>Embryonic stem cells for diabetes</i>	258
<i>HSC transplantation to supplement immunosuppressant therapy</i>	259
<i>Insulin-producing cells derived from UCB stem cells</i>	259
<i>iPSc for diabetes</i>	260
<i>Pancreatic stem cells</i>	260
<i>Stem cell injection into portal vein of diabetic patients</i>	261
Conversion of progenitor cells into insulin-producing cells	261
<i>Human neural progenitor cells converted into insulin-producing cells</i>	261
<i>Isolation of islet progenitor cells</i>	261
<i>Pancreatic progenitor cells</i>	262
Cell-based immunotherapy for type 1 diabetes	262
<i>Dendritic cell-based therapy</i>	262
<i>T regulatory cell therapy for diabetes</i>	263
<i>Vaccine for diabetes</i>	263
Gene therapy in diabetes	263
<i>Viral vectors for gene therapy of diabetes</i>	263
<i>Genetically engineered dendritic cells</i>	264
<i>Genetically altered liver cells</i>	264
<i>Genetically modified stem cells</i>	264
Companies developing cell therapy for diabetes	265
Concluding remarks about cell and gene therapy of diabetes	265
Cell therapy of gastrointestinal disorders	267
Inflammatory bowel disease	267
Cell therapy for liver disorders.....	267
Types of cells used for hepatic disorders	267
<i>Culture and expansion of primary human hepatocytes</i>	268
<i>Hepatocyte progenitor cells</i>	268
<i>Hybrid periportal hepatocytes</i>	269
Methods of delivery of cells for hepatic disorders.....	269
Hepatic failure	269
Bioartificial liver	270
<i>Hepatocyte-based artificial liver</i>	270
<i>Extracorporeal Liver Assist Device</i>	270
<i>Limitations of bioartificial liver</i>	271
<i>Proliferating cell-based bioartificial liver</i>	271
Stem cells for hepatic disorders	271
<i>Deriving hepatocytes from commercially available hMSCs</i>	272
<i>Implantation of hepatic cells derived from hMSCs of adipose tissue</i>	272
<i>Heterologous adult liver progenitor cells</i>	272
<i>Liver stem cell culture</i>	273
<i>MSC derived molecules for reversing hepatic failure</i>	273
Cell-based gene therapy for liver disorders.....	273
<i>Transplantation of genetically modified fibroblasts</i>	274
<i>Transplantation of genetically modified hepatocytes</i>	274
<i>Genetically modified hematopoietic stem cells</i>	274
<i>iPSCs derived from somatic cells for liver regeneration</i>	275
<i>Hepatocyte-like cells derived from human parthenogenetic stem cells</i>	275
Clinical applications	275

Future prospects of cell-based therapy of hepatic disorders	276
Cell therapy of renal disorders	277
Bioartificial kidney	277
Cell-based repair for vascular access failure in renal disease	277
Mesangial cell therapy for glomerular disease	278
Stem cells for renal disease	278
<i>Role of stem cells in renal repair</i>	278
<i>Bone marrow stem cells for renal disease</i>	279
<i>Human amniotic fluid stem cells for renal regeneration</i>	279
<i>MSC therapy for renal disease</i>	279
<i>MSCs as aid to renal graft survival</i>	280
Transplantation of cell-based bioengineered kidney	280
Cell therapy for pulmonary disorders	281
Delivery of cell therapy for pulmonary disorders	281
<i>Intratracheal injection of cells for pulmonary hypoplasia</i>	281
Role of stem cells in pulmonary disorders.....	281
<i>Lung stem cells</i>	281
<i>Lung tissue regeneration from stem cells</i>	282
<i>Role of autologous MSCs in the treatment of severe emphysema</i>	282
<i>Role of stem cells in construction of the Cyberlung</i>	282
<i>Respiratory epithelial cells derived from UCB stem cells</i>	283
<i>Respiratory epithelial cells derived from hESCs</i>	283
<i>Lung tissue engineering with adipose stromal cells</i>	283
<i>Cell-based tissue-engineering of airway</i>	284
Pulmonary disorders that can be treatable with stem cells.....	285
<i>Acute lung injury and ARDS treated with MSCs</i>	285
<i>Bronchopulmonary dysplasia treated with MSCs</i>	286
<i>Chronic obstructive pulmonary disease treated with MSCs</i>	286
<i>Cystic fibrosis treatment with genetically engineered MSCs</i>	287
<i>Idiopathic pulmonary fibrosis</i>	287
<i>Lung regeneration by integrin $\alpha\beta4$-expressing alveolar epithelial cell</i>	287
<i>Pulmonary arterial hypertension treatment with EPCs</i>	287
Cell therapy for disorders of bones, joints and tendons	288
Cell therapy for repair of fractures and bone defects.....	288
<i>Bone regeneration by human very small embryonic-like (hVSEL) cells</i>	289
<i>Cell therapy for cervical vertebral interbody fusion</i>	290
<i>Cell-mediated gene therapy for bone regeneration</i>	290
<i>ESCs for bone repair</i>	290
<i>hiPSCs for engineering personalized bone grafts</i>	290
<i>Intrauterine use of MSCs for osteogenesis imperfecta</i>	290
<i>In vivo bone engineering as an alternative to cell transplantation</i>	291
<i>In vivo differentiation of pluripotent stem cells for bone regeneration</i>	291
<i>MSCs for repair of bone defects</i>	291
<i>MSCs for repair of bone fractures</i>	294
<i>Osteocel</i>	295
<i>Stem cells for repairing skull defects</i>	295
<i>Stem cell-based bone tissue engineering</i>	296
<i>Spinal fusion using stem cell-based bone grafts</i>	297
<i>Wnt stimulation to enrich BMSCs for repair of bone fractures</i>	297
Cell therapy of tendon injuries	297
<i>Autologous tenocyte implantation in rotator cuff injury repair</i>	298
<i>Platelet injection for tennis elbow</i>	298
Cell-based techniques for cartilage repair and regeneration	299
<i>Cartilage generation from stem cells</i>	299
<i>Cartilage engineering from iPSCs</i>	300
<i>Genetically modified fibroblasts expressing TGF-β for cartilage repair</i>	300
<i>Juvenile cartilage implant for repair of damage to articular cartilage</i>	301
Cell therapy for repair of knee cartilage injuries	301
<i>Autologous chondrocyte therapy of the knee</i>	302
<i>Meniscus-derived stem cells</i>	303
<i>MSC-based constructs for knee joint replacement</i>	303
<i>Nanobiotechnology scaffolds for MSC-based cartilage reconstruction</i>	303
<i>Role of cells in the repair of anterior cruciate ligament injury</i>	304
Osteoporosis	304
<i>Stem cell gene therapy for osteoporosis</i>	304
Osteoarthritis of the joints	305
<i>Autologous cultured chondrocytes</i>	305
<i>Autologous intervertebral disc chondrocyte transplantation</i>	306
<i>Intraarticular MSCs for osteoarthritis</i>	307
<i>Mosaicplasty</i>	307
<i>Stem cell therapy of osteoarthritis of the knee</i>	307

Osteonecrosis	308
<i>Cell therapy for osteonecrosis</i>	308
<i>Cell therapy for radionecrosis</i>	308
<i>Repair of osteonecrosis by bone marrow derived MSCs</i>	309
Rheumatoid arthritis.....	309
Cell therapy for diseases of the eye	309
Cell therapy for corneal repair	310
Lens regeneration from endogenous stem cells	311
Stem cell therapy for limbal stem cell deficiency	311
Role of stem cells in fibrosis following eye injury	312
Stem cell transplantation for radiation sickness	312
MSCs for treatment of radiation damage to the bone	313
MSCs for regeneration of ovaries following radiotherapy damage	313
Cell therapy for wound healing	313
Cells to form skin substitutes for healing ulcers	314
CellSpray for wound repair	314
Cell therapy for burns.....	315
Closure of incisions with laser guns and cells	316
Genetically engineered keratinocytes for wound repair.....	316
MSCs for wound healing.....	316
Role of amniotic fluid MSCs in repair of fetal wounds	317
Role of cells in regenerative medicine.....	317
Stem cells for regeneration of skin and appendages	317
<i>Bifunctional ectodermal stem cells and nail regeneration</i>	317
<i>Stem cells for regeneration of skin in junctional epidermolysis bullosa</i>	317
<i>Follicular stem cells for skin and wound repair</i>	318
<i>Regeneration of aging skin by adipose-derived stem cells</i>	319
<i>Reprogramming autologous stem cells for regeneration of skin</i>	319
<i>Concluding remarks on regeneration of skin by stem cells</i>	319
Cell therapy for regeneration of muscle wasting.....	319
Role of stem cells in regeneration of esophageal epithelium	320
Stem cell-based regenerative therapy for xerostomia	320
Concluding remarks for use of cells in regenerative medicine.....	320
<i>Genomic studies for examining the role of stem cells in regeneration</i>	321
<i>Cell therapy for regenerating organs</i>	321
<i>Umbilical cord blood for regeneration</i>	322
Future prospects of stem cells for regenerative medicine	322
Role of cells in tissue engineering and reconstructive surgery	323
Scaffolds for tissue engineering	323
Improving vascularization of engineered tissues	323
<i>Reconstruction of vasculature</i>	323
Repair of aging skin by injecting autologous fibroblasts.....	324
Enhancing vascularization by combining cell and gene therapy	324
Nanobiotechnology applied to cells for tissue engineering.....	325
Choosing cells for tissue engineering	325
Stem cells for tissue repair.....	326
<i>ESCs vs adult SCs for tissue engineering</i>	326
<i>Use of adult MSCs for tissue engineering</i>	327
<i>Measuring MSC interactions with environment for tissue engineering</i>	327
Stem cells for tissue engineering of various organs	328
<i>Breast reconstruction by adipose tissue-derived stem cells</i>	328
<i>Engineering of healthy living teeth from stem cells</i>	328
<i>Intra-uterine repair of congenital defects using amniotic fluid MSCs</i>	329
<i>Skin regeneration by stem cells as an alternative to face transplant</i>	330
<i>Tissue engineering of bone by stem cells</i>	330
Cell-based tissue engineering in genitourinary system	331
<i>Urinary incontinence</i>	331
<i>Tissue engineering of urinary bladder</i>	332
<i>Label retaining urothelial cells for bladder repair</i>	333
<i>MSCs for bladder repair</i>	333
<i>Tissue-engineering of urethra using autologous cells</i>	333
<i>Repair of the pelvic floor with stem cells from the uterus</i>	334
<i>Reconstruction of vagina from stem cells</i>	334
Reconstruction of cartilage for repair of craniofacial defects.....	334
Intraoperative cell therapy	335
Cell therapy for rejuvenation	335
Reversal of muscle weakness and atrophy in aging	336
Reversal of cognitive impairment in aging	336
Cell therapy for performance enhancement in sports	336
Application of stem cells in veterinary medicine	336
Use of stem cells to repair tendon injuries	336

Stem cells for spinal cord injury in dogs	337
5. Cell Therapy for Cardiovascular Disorders	339
Introduction to cardiovascular disorders	339
Limitations of current therapies for myocardial ischemic disease	339
Types of cell therapy for cardiovascular disorders	339
Cell-mediated immune modulation for chronic heart disease	341
Inducing the proliferation of cardiomyocytes	341
Pericardial origin of colony-forming units	342
Role of splenic myocytes in repair of the injured heart	342
Reprogramming of fibroblasts into functional cardiomyocytes	342
Stem cell-based therapies for cardiovascular diseases	343
<i>Human cardiovascular progenitor cells</i>	<i>343</i>
<i>Human pluripotent stem cell-derived cardiomyocytes</i>	<i>344</i>
<i>Magnetic antibody-linked nanoparticles to deliver cells to the heart</i>	<i>344</i>
<i>Role of the SDF-1-CXCR4 axis in therapies for myocardial ischemia</i>	<i>344</i>
<i>Small molecules to enhance myocardial repair by stem cells</i>	<i>344</i>
<i>Stem cells and atherosclerosis</i>	<i>345</i>
Cell therapy for atherosclerotic coronary artery disease	345
MyoCell™ (Bioheart)	346
Cardiac stem cells	346
Cardiomyocytes derived from epicardium	347
Cardiac atrial appendage stem cells	348
Methods of delivery of cells to the heart	348
Cellular cardiomyoplasty	348
IGF-1 delivery by nanofibers to improve cell therapy for MI	348
Non-invasive delivery of cells to the heart by Morph@guide catheter	349
Cell therapy for cardiac revascularization	349
Transplantation of cardiac progenitor cells for revascularization of myocardium	349
Stem cells to prevent restenosis after coronary angioplasty	349
Role of cells in cardiac tissue repair	350
Modulation of cardiac macrophages for repair of infarct	350
Transplantation of myoblasts for myocardial infarction	350
Patching myocardial infarction with fibroblast culture	351
Cardiac repair with myoendothelial cells from skeletal muscle	352
Myocardial tissue engineering	352
Role of stem cells in repair of the heart	353
Role of stem cells in cardiac regeneration following injury	353
Cardiomyocytes derived from adult skin cells	353
Cardiomyocytes derived from ESCs	354
Cardiomyocyte differentiation from hIPSCs	356
Studies to identify subsets of progenitor cells suitable for cardiac repair	356
Technologies for preparation of stem cells for cardiovascular therapy	356
<i>Pravastatin for expansion of endogenous progenitor and stem cells</i>	<i>356</i>
<i>Cytokine preconditioning of human fetal liver CD133+ SCs</i>	<i>357</i>
<i>Expansion of adult cardiac stem cells for transplantation</i>	<i>357</i>
<i>Role of MSCs in growth of CSCs</i>	<i>358</i>
Role of ESCs in repair of the heart	358
<i>ESC transplantation for tumor-free repair of the heart</i>	<i>359</i>
Transplantation of stem cells for myocardial infarction	359
<i>Autologous bone marrow-derived stem cell therapeutics</i>	<i>359</i>
<i>Autologous bone marrow-derived mesenchymal precursor stem cells</i>	<i>360</i>
<i>Intracoronary infusion of mobilized peripheral blood stem cells</i>	<i>360</i>
<i>Transplantation of cord blood stem cells</i>	<i>361</i>
<i>Transplantation of hESCs</i>	<i>361</i>
<i>Transplantation of HSCs</i>	<i>361</i>
<i>Transplantation of autologous angiogenic cell precursors</i>	<i>362</i>
<i>Transplantation of adipose-derived stem cells</i>	<i>362</i>
<i>Transplantation of bone marrow-derived cells for myocardial infarct</i>	<i>363</i>
<i>Transplantation of human umbilical cord perivascular cells</i>	<i>364</i>
<i>Transplantation of endothelial cells</i>	<i>364</i>
<i>Transplantation of cardiomyocytes differentiated from hESCs</i>	<i>365</i>
Stem cell therapy for cardiac regeneration	365
<i>3D printed scaffold for regeneration of myocardial infarct with cells</i>	<i>365</i>
<i>Cryopreserved hESC-derived cardiomyocytes for cardiac regeneration</i>	<i>366</i>
<i>HSCs for regeneration of the chronic myocardial infarcts</i>	<i>366</i>
<i>Human MSCs for cardiac regeneration</i>	<i>366</i>
<i>In vivo tracking of MSCs transplanted in the heart</i>	<i>367</i>
<i>MSCs for hibernating myocardium</i>	<i>368</i>
<i>Simultaneous transplantation of MSCs and skeletal myoblasts</i>	<i>368</i>
Transplantation of genetically modified cells	368

Transplantation of genetically modified MSCs	368
Transplantation of cells secreting vascular endothelial growth factor.....	369
Transplantation of genetically modified bone marrow stem cells.....	369
Cell transplantation for congestive heart failure.....	369
AngioCell gene therapy for congestive heart failure	370
Injection of adult stem cells for CHF	370
Intracoronary infusion of cardiac stem cells.....	371
Myoblasts for treatment of congestive heart failure	371
Stem cell therapy for dilated cardiac myopathy.....	371
Role of cell therapy in cardiac arrhythmias	372
Biological pacemakers	372
<i>Stem cells as biological pacemakers</i>	<i>372</i>
<i>Stem cells for cardiac arrhythmias</i>	<i>374</i>
Prevention of myoblast-induced arrhythmias by genetic engineering	374
Ventricular tachycardia	374
ESCs for correction of congenital heart defects.....	375
Cardiac progenitors cells for treatment of heart disease.....	375
Autologous stem cells for chronic myocardial ischemia	376
Role of cells in cardiovascular tissue engineering	376
Cell-based in vitro regeneration of heart for transplantation	376
Construction of blood vessels with cells.....	377
<i>Engineered arteries for bypass grafts.....</i>	<i>377</i>
Engineering heart valves with UCB progenitor cells	378
Epicardial regeneration from hPSCs	378
Fetal cardiomyocytes seeding in tissue-engineered cardiac grafts.....	378
Targeted delivery of endothelial progenitor cells labeled with nanoparticles	378
Cell therapy for peripheral vascular disease	379
ALD-301	379
Cell/gene therapy for PVD.....	379
Cell therapy for CLI in diabetics	379
Colony stimulating factors for enhancing peripheral blood stem cells	380
Intramuscular autologous bone marrow cells.....	380
Ixmyelocel-T cell therapy for critical limb ischemia	380
Stem cell-coated vascular grafts for femoral-tibial arterial bypass	381
Clinical trials of cell therapy in cardiovascular disease	381
Mechanism of the benefit of cell therapy for heart disease	384
A critical evaluation of cell therapy for heart disease	384
Publications of clinical trials of cell therapy for CVD	385
Current status of cell therapy for cardiovascular disease	385
Future directions for cell therapy of CVD	386
Combination of cells with biomedical scaffolds	386
Prospects of adult stem cell therapy for repair of heart	386
Role of cells in regeneration of the heart.....	387
Regeneration of cardiomyocytes without use of cardiac stem cells.....	387

6. Cell Therapy for Cancer.....	389
Introduction.....	389
Cell therapy technologies for cancer	389
Cell-based delivery of anticancer therapy	390
Cellular immunotherapy for cancer	390
Treatments for cancer by ex vivo mobilization of immune cells	391
Granulocytes as anticancer agents	391
Neutrophil granulocytes in antibody-based immunotherapy of cancer	392
Cancer vaccines	392
Autologous tumor cell vaccines	392
<i>BIOVAXID</i>	<i>392</i>
<i>OncovAX.....</i>	<i>393</i>
<i>Tumor cells treated with dinitrophenyl</i>	<i>393</i>
Vaccines that simultaneously target different cancer antigens.....	393
Gene modified cancer cells vaccines	394
<i>GVAX cancer vaccines.....</i>	<i>394</i>
<i>K562/GM-CSF.....</i>	<i>394</i>
Active immunotherapy based on antigen specific to the tumor	395
The use of dendritic cells for cancer vaccination	395
<i>Autologous dendritic cells loaded ex vivo with telomerase mRNA.....</i>	<i>395</i>
<i>Dendritic cell-targeted protein vaccines.....</i>	<i>396</i>
<i>Dendritic/tumor cell fusion</i>	<i>396</i>
<i>Electro-hyperthermia for improving DC immunotherapy.....</i>	<i>396</i>
<i>Genetically modified dendritic cells.....</i>	<i>397</i>
<i>In vivo manipulation of dendritic cells.....</i>	<i>397</i>
<i>Preclinical and clinical studies with DC vaccines</i>	<i>397</i>

<i>Vaccines based on dendritic cell-derived exosomes</i>	398
<i>Limitations of DC vaccines for cancer</i>	398
<i>Future developments to enhance clinical efficacy of DC vaccines</i>	399
Cell-based cancer immunotherapy	400
<i>Adoptive cell therapy</i>	400
<i>CD8+ T cells for use in tumor immunotherapy</i>	401
<i>Chimeric antigen receptor T cells</i>	402
<i>ProCAR-NK cancer immunotherapy</i>	404
<i>Combination of antiangiogenic agents with ACT</i>	405
<i>Expansion of antigen-specific cytotoxic T lymphocytes</i>	405
<i>Genetically modified T cells for targeting tumors</i>	405
<i>Genetic engineering of tumor cells to activate T helper cells</i>	406
<i>Targeting T regulatory cells</i>	406
<i>T cells with immunological memory and stem cell-like properties</i>	406
<i>Tumor infiltrating lymphocytes</i>	407
Hybrid cell vaccination	407
Chemoimmunotherapy	408
Stem cell-based anticancer therapies	408
Stem cell transplantation in cancer.....	408
<i>Peripheral blood stem cell transplantation</i>	408
<i>Stem cell transplantation for hematological malignancies</i>	411
<i>Long-term results of HSC transplantation</i>	412
<i>Prediction of T cell reconstitution after HSC transplantation</i>	413
<i>HSC transplantation followed by GM-CSF-secreting cell vaccines</i>	413
<i>HSC transplantation for renal cell cancer</i>	414
<i>Umbilical cord blood transplant for hematological malignancies</i>	414
Complications of stem cell transplants in cancer.....	415
<i>Graft-versus-host disease (GVHD)</i>	415
<i>Delayed immune reconstitution leading to viral infections and relapse</i>	415
<i>Tumor cell contamination</i>	416
<i>Neurological complications</i>	416
<i>Hepatic veno-occlusive disease</i>	416
<i>Current status and safety of allogeneic HSC transplantation</i>	417
<i>Complications of PBSC transplantation in children</i>	417
Role of MSCs in cancer	418
<i>MSC-mediated delivery of anticancer therapeutics</i>	418
<i>Mesenchymal progenitor cells for delivery of oncolytic adenoviruses</i>	418
<i>MSCs for oncolytic HSV delivery for brain metastases of melanoma</i>	419
Nonmyeloablative allogeneic hematopoietic stem cell transplantation	419
hESC-derived NK cells for treatment of cancer	420
ESC vaccine for prevention of lung cancer	420
Genetic modification of stem cells for cancer therapy.....	420
<i>Genetic modification of hematopoietic stem cells</i>	420
<i>Use of hematopoietic stem cells to deliver suicide genes to tumors</i>	421
<i>Delivery of anticancer agents by genetically engineered MSCs</i>	421
<i>Genetically modified NSCs for treatment of neuroblastoma</i>	422
Innovations in cell-based therapy of cancer	422
Use of immortalized cells	422
Cancer therapy based on natural killer cells.....	423
Cytokine-induced killer cells	423
Mesothelin as a target for cancer immunotherapy	423
Nanomagnets for targeted cell-based cancer gene therapy.....	424
Implantation of genetically modified encapsulated cells for anticancer therapy	424
<i>Antiangiogenesis therapy by implantation of microencapsulated cells</i>	424
<i>Recombinant tumor cells secreting fusion protein</i>	424
<i>A device for filtering cancer and stem cells in the blood</i>	425
Cancer stem cells.....	425
<i>Cancer stem cell biomarkers</i>	425
<i>Integrative nuclear signaling and development of cancer in stem cells</i>	426
<i>Origin of cancer in normal stem cells</i>	426
<i>Role of intestinal stem cells in intestinal polyposis</i>	426
<i>Role of endothelial progenitor cells in tumor angiogenesis</i>	427
<i>Role of cancer stem cells in metastases</i>	427
<i>Therapeutic implications of cancer stem cells</i>	427
<i>Targeting breast cancer stem cells</i>	428
<i>Targeting cancer stem cells in leukemia</i>	429
<i>Targeting cancer stem cells in ovarian cancer</i>	429
<i>Targeting cancer stem cells to screen anticancer drugs</i>	430
Companies involved in cell-based cancer therapy	430
American Association for Cancer Research and ESCs	431
Future of cell-based immunotherapy for cancer	432

7. Cell Therapy for Neurological Disorders.....	434
Introduction.....	434
Use of stem cells for research in neurosciences.....	434
Cerebral organoids for modeling human brain development.....	434
Use of human stem cell-derived neurons in neuropharmacology	434
Regeneration of brain by in vitro/in vivo reprogramming of cells.....	435
Molecular mechanism of neurogenesis	436
Generation of neurons from astroglia.....	437
In vivo cell replacement therapy by locally induced neural progenitor cells	437
In vivo reprogramming to generate new neurons	437
Types of cells used for treatment of neurological disorders	438
Activated T lymphocytes	439
Differentiation of placenta-derived multipotent cells into neurons.....	439
Fibroblast-derived human striatal neurons.....	439
Mesenchymal stem cells induced to secrete neurotrophic factors	439
MUSE cells transplantation for neuronal regeneration	440
Neural stem cells	440
<i>Development of human CNS stem cells</i>	<i>440</i>
<i>Direct conversion of adult fibroblasts into neural progenitor cells</i>	<i>441</i>
<i>Distinction between NSCs and intermediate neural progenitors</i>	<i>441</i>
<i>Embryonic stem cell-derived neurogenesis</i>	<i>441</i>
<i>Epidermal neural crest stem cells for neurological disorders</i>	<i>442</i>
<i>Fusion of NSCs with endogenous neurons</i>	<i>442</i>
<i>Induction of NSCs from hESCs</i>	<i>442</i>
<i>Induction of NSCs from adult MSCs</i>	<i>444</i>
<i>Mechanism of migration of NSCs to sites of CNS injury</i>	<i>444</i>
<i>Monitoring of implanted NSCs labeled with nanoparticles</i>	<i>444</i>
<i>Neural progenitor cells.....</i>	<i>444</i>
<i>Neural stem cells in the subventricular zone of the brain.....</i>	<i>447</i>
<i>Oligodendrocyte progenitor cells</i>	<i>447</i>
<i>Promotion of neural stem cells expansion by betacellulin.....</i>	<i>447</i>
<i>Proteomics of neural stem cells.....</i>	<i>447</i>
<i>Regulation of neural stem cells in the brain</i>	<i>448</i>
<i>Role of CSF proteins in regulation of neural progenitor cells.....</i>	<i>449</i>
<i>Sequencing the transcriptomes of neural stem cells.....</i>	<i>449</i>
<i>Study of neural differentiation of hESCs by NeuroStem Chip.....</i>	<i>450</i>
<i>Transformation of neural stem cells into other cell types</i>	<i>450</i>
Stem cell transplantation in the CNS	450
<i>Development of CNS cells from non-CNS stem cells.....</i>	<i>450</i>
<i>Expansion of adult human neural progenitors</i>	<i>451</i>
<i>Hair-follicle stem cells for neural repair</i>	<i>451</i>
<i>Human NSCs for treatment of neurological disorders</i>	<i>452</i>
<i>NSCs and scaffolds for regeneration therapy of CNS disorders</i>	<i>453</i>
<i>Neurospheres</i>	<i>453</i>
<i>Stem cells from olfactory epithelium for transplantation in the CNS.....</i>	<i>453</i>
<i>Stem cells from human umbilical cord blood for CNS disorders</i>	<i>453</i>
Choroid plexus cells for transplantation.....	454
Dental pulp cells for neuroprotection	454
Derivation of CNS cells from peripheral nervous system.....	454
Fetal tissue transplants.....	455
Immortalized cells for CNS disorders	455
Laboratory mice with human brain cells	456
Olfactory ensheathing cells for CNS repair.....	456
Ideal cells for transplantation into the nervous system	457
Cell therapy techniques for neurological applications	457
Carbon nanotubes to aid stem cell therapy of neurological disorders	457
Cell transplantation for regeneration of the nervous system	457
Cells used for gene therapy of neurological disorders.....	458
<i>Fibroblasts</i>	<i>458</i>
<i>Stem cells.....</i>	<i>458</i>
<i>Neuronal cells.....</i>	<i>459</i>
<i>Immortalized neural progenitor cells.....</i>	<i>459</i>
<i>Astrocytes.....</i>	<i>459</i>
<i>Cerebral endothelial cells</i>	<i>460</i>
<i>Human retinal pigmented epithelial cells</i>	<i>460</i>
Enhancement of growth of stem cells in the brain by drugs	460
<i>C3-induced differentiation and migration of NPC for repair of the brain</i>	<i>461</i>
Stem cell therapies of neurological disorders combined with HBO.....	461
hESCs for CNS repair.....	462
Motor neurons derived from stem cells	462
MSCs for CNS repair.....	462

Neuronal differentiation of stem cells.....	463
<i>Apigenin promotes differentiation of stem cells into neural lineage</i>	464
Stem cells preparations for CNS disorders.....	464
Tracking of stem cells in the CNS by nanoparticles and MRI	465
Use of neural stem cells to construct the blood brain barrier.....	465
Methods of delivery of cells to the CNS	466
<i>Cerebrospinal fluid-stem cell interactions for therapy of CNS disorders</i>	466
<i>CNS delivery of cells by catheters</i>	466
<i>Engineered stem cells for drug delivery to the brain</i>	467
<i>Encapsulated cells</i>	467
<i>Intrathecal delivery of stem cells</i>	467
<i>Intraparenchymal delivery of stem cells to the spinal cord</i>	468
<i>Intravascular administration</i>	468
<i>Neural stem cells as therapeutic delivery vehicles</i>	469
Neurological disorders amenable to cell therapy	469
Neuroprotection by cell therapy	470
<i>Cells secreting neuroprotective substances</i>	470
<i>Stem cells for neuroprotection</i>	470
<i>Neuroprotection by intravenous administration of HSCs</i>	470
<i>Human UCB-derived stem cells for the aging brain</i>	470
Neurodegenerative disorders	471
<i>MSCs for therapy of neurodegenerative disorders</i>	471
<i>Role of stem cells in neurodegenerative disorders</i>	472
<i>Role of NSCs in disorders associated with aging brain</i>	473
<i>NSCs for improving memory</i>	473
Parkinson's disease	473
<i>Cell therapies for PD</i>	474
<i>Delivery of cells for PD</i>	475
<i>Dopamine neurons for PD</i>	476
<i>Encapsulated cells for PD</i>	476
<i>Graft survival-enhancing drugs</i>	477
<i>Human retinal pigment epithelium cells for PD</i>	477
<i>Potential of regeneration of endogenous stem cells in PD</i>	478
<i>Pluripotent stem cell-derived neurons</i>	478
<i>Stem cell transplantation in animal models of PD</i>	479
<i>Stem cells for production of glial derived neurotrophic factor</i>	480
<i>Transplantation of embryonic medial ganglionic eminence cells</i>	481
<i>Trials of stem cell transplantation in PD patients</i>	481
<i>Tumorigenic potential of transplanted dopaminergic hESCs</i>	482
<i>Xenografting porcine fetal neurons</i>	483
<i>Personalized stem cell therapy for PD</i>	483
<i>Future perspectives of clinical trials of stem cell therapy for PD</i>	484
MSCs for multiple system atrophy	484
Cell therapy for Huntington's disease.....	485
<i>Fetal striatal cell transplantation</i>	485
<i>Transplantation of encapsulated porcine choroids plexus cells</i>	485
<i>iPSCs for HD</i>	486
<i>Mobilization of endogenous neural progenitor cells in HD</i>	486
Cell therapy for Alzheimer's disease	486
<i>Choroid plexus epithelial cells for AD</i>	486
<i>Implantation of genetically engineered cells producing NGF</i>	487
<i>Implantation of stem cells derived from the skin</i>	487
<i>Neural stem cell implantation for Alzheimer's disease</i>	487
Cell therapy for amyotrophic lateral sclerosis.....	488
<i>Stem cell techniques for study of ALS</i>	488
<i>Rational for use of stem cells for ALS</i>	489
<i>Experimental studies with various types of stem cells for ALS</i>	489
<i>Clinical trials of stem cells for ALS</i>	491
<i>Transplantation of glial restricted precursors in ALS</i>	492
<i>Stem cell-based drug discovery for ALS</i>	492
Cell therapy for demyelinating disorders	493
<i>Autologous bone marrow stem cell therapy for multiple sclerosis</i>	493
<i>ESCs for remyelination</i>	493
<i>Fusokine method of personalized cell therapy of MS</i>	494
<i>Genetically engineered macrophages expressing Nav1.5</i>	494
<i>Hematopoietic stem cell transplantation for MS</i>	494
<i>Mechanism of repair of demyelination after NSC transplantation</i>	495
<i>MSCs for multiple sclerosis</i>	495
<i>Neural progenitor cells for neuroprotection in MS</i>	496
<i>Oligodendrocyte generation from human iPSCs</i>	496
<i>T cell-based personalized vaccine for MS</i>	497

<i>Stem cells for chronic inflammatory demyelinating polyneuropathy</i>	497
<i>Stem cell transplantation for Pelizaeus-Merzbacher disease</i>	497
<i>X-linked adrenoleukodystrophy</i>	498
Cell therapy of stroke	498
<i>Adult stem cell therapy in stroke</i>	499
<i>Cell therapy of intracerebral hemorrhage</i>	499
<i>Implantation of genetically programmed ESCs</i>	500
<i>Intravenous infusion of MSCs</i>	500
<i>Intravenous infusion of human UCB stem cells</i>	501
<i>Intracerebral administration of human adipose tissue stromal cells</i>	501
<i>Neural stem cell therapy for stroke</i>	502
<i>Transplantation of encapsulated porcine choroids plexus</i>	503
<i>Transplantation of fetal porcine cells</i>	503
<i>Role of cell therapy in management of stroke according to stage</i>	503
<i>Clinical trials of cell therapy for stroke</i>	504
<i>Future of cell therapy for stroke</i>	505
Cell therapy of traumatic brain injury	506
<i>Cell/gene therapy for TBI</i>	507
<i>Clinical trials of autologous stem cell therapy for TBI</i>	507
<i>Limitations of stem cell therapy for acute TBI</i>	508
<i>Improving the microenvironments of transplanted cells in TBI</i>	508
<i>MSC-derived exosomes for treatment of TBI</i>	508
Cell therapy for spinal cord injury	509
<i>Autoimmune T cells against CNS myelin-associated peptide</i>	509
<i>Fetal neural grafts for SCI</i>	509
<i>Olfactory-ensheathing cells for SCI</i>	509
<i>Oligodendrocyte precursor cells for treatment of SCI</i>	510
<i>Schwann cell transplants for SCI</i>	510
<i>Transplantation of glial cells for SCI</i>	510
Stem cells for SCI	511
<i>Bone marrow stem cells for SCI</i>	511
<i>Embryonic stem cells for SCI</i>	511
<i>ESC-derived neural aggregates for treatment of SCI</i>	512
<i>Transplantation of induced pluripotent stem cells in SCI</i>	513
<i>Transplantation of MSCs for SCI</i>	513
<i>Transplantation of NSCs for SCI</i>	513
<i>Transplantation of human dental pulp stem cells</i>	514
<i>Transdifferentiation of BM stem cells into cholinergic neurons for SCI</i>	514
<i>Evaluation of experimental studies of stem cell transplantation in SCI</i>	515
Spinal stem cells for treatment of ischemic injury of spinal cord	515
Combined approaches for regeneration in SCI	515
<i>Combined cell/gene therapy for SCI</i>	516
Delivery of cells in SCI.....	516
<i>Intrathecal injection of cells labeled with magnetic nanoparticles</i>	517
<i>Intravenous injection of stem cells for spinal cord repair</i>	517
Clinical applications of stem cells for SCI.....	517
<i>Autologous bone marrow cell transplantation for SCI</i>	517
<i>Cell therapy of syringomyelia</i>	518
Cell therapy for neurogenetic disorders	518
<i>Hurler's syndrome treated with stem cells</i>	518
<i>Krabbe's disease treated with UCB stem cells</i>	519
<i>Krabbe's disease treated with combination of cell and gene therapy</i>	519
<i>Mitochondrial encephalomyopathies treated with stem cells</i>	520
<i>Sanfilippo syndrome type B treated with UCB stem cells</i>	520
Cell therapy for lysosomal storage disorders.....	521
<i>Cell therapy for Batten disease</i>	521
<i>Cell/gene therapy for Farber's disease</i>	521
<i>Genetically modified HSCs for metachromatic leukodystrophy</i>	522
<i>Neural stem cells for lysosomal storage disorders</i>	522
Cell therapy of epilepsy	522
<i>Cell therapy of posttraumatic epilepsy</i>	523
<i>Cell therapy for temporal lobe epilepsy</i>	523
<i>Cell therapy for pharmaco-resistant epilepsies</i>	523
Cell therapy for developmental neurological disorders.....	524
Cell therapy for cerebral palsy	524
Cell-based therapies for malignant CNS tumors	525
<i>Bone morphogenetic protein for inhibition of glioblastoma multiforme</i>	525
<i>Dendritic cell therapy for brain tumors</i>	525
<i>Encapsulated cells for brain tumors</i>	526
<i>Engineered human NSCs for treatment of spinal cord gliomas</i>	526
<i>Immunotherapy of GBM targeting cancer stem cells</i>	527

<i>Mesenchymal stem cells for the treatment of gliomas</i>	527
<i>Neural stem cells for treatment of malignant brain tumors</i>	528
<i>Role of cancer stem cells in resistance to radiotherapy</i>	529
<i>Stem cell-based therapy targeting EGFR in GBM</i>	530
<i>Targeting stem cells in brain tumors</i>	530
<i>Clinical trials of cell therapy of glioblastoma multiforme</i>	530
Cell therapy for chemobrain	530
Cell therapy for muscle disorders	531
<i>Duchenne muscular dystrophy</i>	531
<i>Combination of cell and pharmacotherapy for DMD</i>	532
<i>Myoblast transplant for DMD</i>	532
<i>Myoblast-based gene transfer</i>	532
<i>Myoblasts lacking the MyoD gene</i>	533
<i>Myoblast injection for treatment of other muscular dystrophies</i>	533
<i>Role of satellite cells in the treatment of DMD</i>	533
<i>Stem cells for DMD</i>	534
<i>Wnt7a treatment for DMD</i>	536
Cell therapy for autism	536
Management of chronic intractable pain by cell therapy	536
<i>Implantation of chromaffin cells</i>	537
<i>Role of stem cells in management of pain</i>	537
<i>Implantation of astrocytes secreting enkephalin</i>	538
<i>Cells for delivery of antinociceptive molecules</i>	538
<i>Implantation of genetically engineered cells</i>	538
<i>Cell therapy for low back pain</i>	538
Cell therapy for neuropathic itch	539
Cell therapy for neuroendocrine disorders	539
<i>Pituitary stem cells</i>	539
Cell therapy for regenerating optic pathways	540
Cell therapy for retinal degenerative disorders.....	540
<i>Delivery of CNTF by encapsulated cell intraocular implants</i>	541
<i>Genetically engineered retinal pigmented epithelial cell lines</i>	541
Stem cell-based therapies for retinal degenerative disorders	541
<i>Adipose-derived stem cells for retinal degeneration</i>	542
<i>Adipose-derived stem cells transplantation for diabetic retinopathy</i>	542
<i>ESCs for retinal degenerative disorders</i>	542
<i>hESC-derived RPE cells for macular dystrophy</i>	542
<i>Human retinal stem cells</i>	543
<i>iPSCs for AMD</i>	543
<i>Neuroprotective effect of neural progenitor cell transplantation</i>	544
<i>Stem-cell based therapy for retinitis pigmentosa</i>	545
<i>Stem cell transplantation in the retina</i>	545
<i>Combining stem cell and gene therapies for retinal disorders</i>	545
Clinical trials of cell therapy for retinal degenerative disorders	546
Stem cell therapy for hearing loss	546
Cell therapy for peripheral nerve lesions.....	547
<i>Cell transplants for peripheral nerve injuries</i>	547
<i>Role of adipose-derived stem cells in peripheral nerve regeneration</i>	547
<i>Treatment of diabetic neuropathy with endothelial progenitor cells</i>	548
Complications of cell therapy of neurological disorders	548
Tumor formation after CNS transplantation of stem cells.....	548
<i>Donor stem cell-derived brain tumor</i>	548
<i>Glioproliferative lesion of spinal cord as a complication of cell therapy</i>	548
<i>Uncontrolled differentiation of implanted ESCs</i>	549
Tumorigenicity of ESC-derived retinal progenitor cells	549
Clinical trials of cell therapy in neurological disorders	549
Future of cell therapy of CNS disorders.....	551
8. Ethical, Legal and Political Aspects of Cell therapy	554
Introduction.....	554
Political and ethical aspects of hESC research in the US	554
Ethical issues concerning fetal tissues.....	555
<i>Morality and hESC research</i>	555
Opponents of hESC research in the US	555
<i>Use of hESCs in NIH-supported research</i>	557
<i>Politics of hESC research in the US</i>	557
<i>Public opinion in the US about hESC research</i>	559
<i>Human stem cell cloning in the US</i>	561
<i>Stem cell guidelines of various US institutions</i>	561
Ethics of transplanting human NSCs into the brains of nonhuman primates	562
ESC lines available worldwide.....	563

ESC policies around the world	564
Countries with no defined policies on hESC research.....	564
Australia	564
Canada.....	565
China	566
Denmark.....	566
France	567
Germany.....	567
India	568
Ireland	569
Israel	570
Italy	570
Japan	570
Russia	571
The Netherlands	571
Saudi Arabia.....	572
Singapore	572
South Africa	572
South Korea	573
Spain	573
Sweden	574
Switzerland	574
United Kingdom	575
<i>UK StemCellBank</i>	575
European Union	576
<i>EU guidelines for stem cell research</i>	576
<i>European stem cell bank</i>	578
<i>EMBO's recommendations for stem cell research</i>	578
Public opinion in Europe about hESC research.....	579
United Nations, cloning and nuclear transfer.....	580
The Embryo Project for information on ESC research	580
Concluding remarks about ethics of ESC research	580
Ethical issues concerning umbilical cord blood	581
Legal issues associated with stem cells	581
Stem cell patents.....	581
<i>Stem cell patents in the United States</i>	581
<i>Current status of Thomson patents at WARF</i>	582
<i>Stem cell patents in the European Union</i>	583
Cell therapy tourism	583
9. Safety and Regulatory Aspects of Cell Therapy	586
Introduction	586
Safety issues of cell therapy	586
Immune-mediated reactions to transplanted stem cells	586
Human virus infections associated with stem cell transplantation	587
<i>Herpes simplex virus type 1</i>	587
<i>Cytomegalovirus</i>	587
Opportunistic infections among hematopoietic stem cell transplant recipients	587
Cord colitis syndrome	587
Carcinogenic potential of stem cells and its prevention	588
Regulatory challenges for the clinical use of cell products	588
Prediction of in vivo performance of cell-based therapies	589
FDA safety regulations for cell and tissue products	589
FDA Guidance on license applications for umbilical cord blood products.....	590
Regulation of cord blood banks in the US	590
Regulatory issues for biotechnology-derived drugs	590
Regulation of products for adoptive cell therapy of cancer	591
Regulation of cell selection devices for PBSCs at point of care	591
FDA rules for human cells and tissues	592
FDA regulation of fetal cellular or tissue products	593
<i>FDA and ESC lines</i>	593
FDA and clinical trials using hESCs	593
Cell and gene therapy INDs placed on hold by the FDA	594
Regulatory issues for genetically engineered cell transplants	595
FDA guidelines for human tissue transplantation	595
FDA considers cultured stem cells for therapy as drugs.....	595
FDA perspective on safety-efficacy and risk-benefit of stem cell therapy	595
FDA action against unapproved cell therapy in the US	596
Xenotransplantation	597
Clinical Protocol Review and Oversight.....	597
Informed consent and patient education	598

Xenotransplantation product sources	598
FDA guidelines for xenografts	599
US regulations for manufacture of cell therapy products	600
<i>GMP in USA</i>	601
Regulations relevant to cell therapy in the European Union	601
Regulations about use of stem cells in the EU	603
Guidelines for cell therapy in the UK	603
Quality requirements for ex vivo-expanded MSC products for clinical use	604
European regulations for manufacture of cell therapy products	604
<i>GMP in Europe</i>	605
Global regulation of stem cell approval	605
Transport of stem cells between countries	605
Temperature limitations during transport of stem cells	605
NIH and stem cells	606
hESC lines approved under the new NIH guidelines	606
Clinical trials in cell therapy	606
Assessment of clinical trial registration and publication	607
Misuse of listing on ClinicalTrials.gov to provide unapproved stem cell therapy	607

Tables

Table 1-1: Landmarks in the history of cell therapy	31
Table 1-2: Examples of cells involved in various diseases	37
Table 2-1: Types of human cells used in cell therapy	41
Table 2-2: A selection of companies providing cell culture media	46
Table 2-3: A sampling of companies supplying cell sorters	52
Table 2-4: Companies involved in cell-based drug discovery	62
Table 2-5: Methods of delivery of cells for therapeutic purposes	64
Table 2-6: Therapeutic applications of encapsulated cells	69
Table 2-7: Companies working on encapsulated cell technology	71
Table 2-8: Molecular imaging methods for tracking cells in vivo	77
Table 3-1: Various levels of potency relevant to stem cells	86
Table 3-2: Clinical trials of UCB	114
Table 3-3: Companies involved in cord blood banking as a source of stem cells	117
Table 3-4: Comparison of techniques for nuclear reprogramming of stem cells	121
Table 3-5: Banks of patient-specific iPSC lines	126
Table 3-6: Companies providing iPSCs	127
Table 3-7: Sources of adult human stem cells	132
Table 3-8: Comparison of human stem cells according to derivation	144
Table 3-9: Enhancing engraftment, mobilization and expansion of stem cells	164
Table 3-10: Applications of stem cells	181
Table 3-11: Advantages and limitations of methods for optimizing MSCs	193
Table 3-12: Pharmaceutical manipulation of stem cells	200
Table 3-13: Growth factors with positive effects on stem cells and applications	201
Table 3-14: Examples of drugs that induce granulocytopenia at stem cell level	212
Table 3-15: Academic institutes involved in stem cell research	220
Table 3-16: Companies involved in stem cell technologies	222
Table 4-1: Therapeutic applications of regulatory T cells (Tregs)	240
Table 4-2: Various tissue/cell therapy approaches to the treatment of type 1 diabetes	248
Table 4-3: Companies involved in cell therapy for insulin-dependent diabetes	265
Table 4-4: Major pulmonary disorders potentially treatable by stem cell manipulation	285
Table 4-5: Cell-based repair of knee cartilage damage	302
Table 4-6: Intraoperative cell therapy	335
Table 5-1: Classification of various types of cell therapy for cardiovascular disorders	340
Table 5-2: Clinical trials of cell therapy in cardiovascular disease	381
Table 6-1: Cell therapy technologies used for cancer	389
Table 6-2: Companies involved in developing cell-based therapies for cancer	430
Table 7-1: Studies in rats or mice of in vivo reprogramming of cells for brain repair	438
Table 7-2: NSCs-based approaches for neurological disorders	452
Table 7-3: Experimental use of immortalized cells for CNS disorders	456
Table 7-4: Combination of stem cells and HBO in models of neurological disorders	461
Table 7-5: Therapeutic applications of MSCs for neurological disorders	463
Table 7-6: Methods for delivering cell therapies in CNS disorders	466
Table 7-7: Neurological disorders amenable to cell therapy	469
Table 7-8: Types of cell used for investigative treatment of Parkinson's disease	474
Table 7-9: Status of cell therapies for Parkinson's disease	475
Table 7-10: Role of cell therapy in management of stroke according to stage	503
Table 7-11: Clinical trials of cell therapy for stroke: completed, ongoing and pending	504
Table 7-12: Clinical trials of cell therapy for retinal degenerative disorders	546
Table 7-13: Clinical trials with cell therapy in neurological disorders (excluding stroke)	550
Table 8-1: Listed numbers of ESC lines around the world	563
Table 8-2: Stem cell policies around the world	564

Table 8-3: European public attitudes about research involving human stem cells	579
Table 9-1: Possible adverse reactions and safety issues of cell therapy	586

Figures

Figure 1-1: Interrelationships of cell therapy to other technologies	34
Figure 1-2: Interrelationships of gene, cell and protein therapies	35
Figure 1-3: Engineering of RBCs for drug delivery	39
Figure 3-1: A simplified biological scheme of embryonic stem Cells	86
Figure 3-2: Steps of iPS cell production	122
Figure 3-3: hESC-derived by somatic cell nuclear transfer.....	161
Figure 3-4: Flow chart of development of stem cells with potential bottlenecks.....	227
Figure 4-1: Reprogramming ESCs/iPSCs cells to β -cells for type 1 diabetes.....	260
Figure 4-2: Fluorescently labeled polarized Upcyte® hepatocytes	268
Figure 5-1: Ex vivo vs in vivo approaches to regeneration of the heart	340
Figure 5-2: hESC-derived cardiomyocytes from laboratory to bedside	355
Figure 5-3: Steps in growing a new heart in vitro for transplantation.....	377
Figure 6-1: A scheme of generation and administration of tumor antigen-pulsed dendritic cells	399
Figure 6-2: Chimeric antigen receptor (CAR)-T cells attacking tumor cells.....	402
Figure 6-3: Stem cell transplantation techniques	410
Figure 7-1: Cell-based methods for repair of the brain.....	435
Figure 7-2: Reprogramming methods for in vivo generation of neurons.	436
Figure 7-3: Stem cells that can give rise to neurons	446
Figure 7-4: Sources of dopaminergic neurons for transplantation in Parkinson’s disease	475
Figure 7-5: Scheme of iPSCs for personalized cell therapy of Parkinson disease	484
Figure 7-6: Potential mechanisms of stem cell efficacy in ALS	489
Figure 7-7: Approaches to stem cell therapy in stroke	499